Milestone Triggered in Connection With Filing of New Drug Application in Japan for Arzerra - MENAFN

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Founded in 1999, the company's first marketed antibody, ofatumumab ...

DGAP-Adhoc: Milestone Triggered in Connection with Filing of New Drug Application in Japan for Arzerra (deutsch) - boersennews.de

Dissemination of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. - Milestone payment of DKK 20 million triggered in connection with Japanese New Drug Application filing ...

Genmab Announces Financial Results for the First Quarter 2012 - msnbc.com

Arzerra(r) net sales increased 32% over Q1 2011 New Drug Application for ofatumumab submitted in Japan Amended protocol for ofatumumab Phase III head to head study vs rituximab in DLBCL; moved estimated primary data readout forward Improved ...

DGAP-News: Genmab Announces Financial Results for the First Quarter 2012 - finanztreff

increase was mainly driven by higher Arzerra(r) royalties and the inclusion of one milestone under our collaboration with Lundbeck. -- Operating expenses decreased 5% from DKK 145 million in the first quarter of 2011 to DKK 138 million in the first quarter of 2012.

PRESS RELEASE: MorphoSys to Present MOR208 Preclinical Combination Therapy Data at ASCO Meeting - ad-hoc-news.de

approved therapeutic agents including the small-molecule drugs bendamustine (Ribomustin(®)) and fludarabine (Fludara(®)) as well as the anti-CD20 antibodies rituximab (Rituxan(®)) and ofatumumab (Arzerra(®)) were evaluated for their ability to enhance ...

United States: GSK And Genentech Settle Cabilly Patent Lawsuit - Mondaq

In the lawsuit, started in October 2009, GSK had sought a declaration that the Cabilly II / III patents were invalid, unenforceable and not infringed by the manufacture, use, sale, offer to sell or importation of GSK's ofatumumab (ARZERRA) antibody product.

MorphoSys to Present MOR208 Preclinical Combination Therapy Data at ASCO Meeting - Market Wire

approved therapeutic agents including the small-molecule drugs bendamustine (Ribomustin(®)) and fludarabine (Fludara(®)) as well as the anti-CD20 antibodies rituximab (Rituxan(®)) and ofatumumab (Arzerra(®)) were evaluated for their ability to enhance ...

ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) - Inside Fidelity

(Abstract No. 6507.) Abstract No. 6508 reports on interim results from a phase Ib/II study combining ibrutinib with Glaxo's Arzerra in patients with relapsed/refractory CLL. The overall response rate to the combination therapy was 100%, all partial responses.

Genmab A/S : Daratumumab Clinical Data to Be Presented at ASCO and EHA - 4-traders (press release)

Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development.  Genmab's ...